ID
23353
Description
A Study of MabThera (Rituximab) in Primary Central Nervous System Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00517699
Link
https://clinicaltrials.gov/show/NCT00517699
Keywords
Versions (3)
- 6/29/17 6/29/17 -
- 7/3/17 7/3/17 - Julian Varghese
- 9/20/21 9/20/21 -
Uploaded on
July 3, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Lymphoma NCT00517699
Eligibility Lymphoma NCT00517699
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
ID.5
Data type
boolean
Alias
- UMLS CUI [1]
- C0392920
Description
ID.6
Data type
boolean
Alias
- UMLS CUI [1]
- C0079172
Description
non hodgkin lymphoma
Data type
boolean
Alias
- UMLS CUI [1]
- C0024305
Description
ID.8
Data type
boolean
Alias
- UMLS CUI [1]
- C0012634
Description
ID.9
Data type
boolean
Alias
- UMLS CUI [1]
- C3714514
Similar models
Eligibility Lymphoma NCT00517699
- StudyEvent: Eligibility
C4289894 (UMLS CUI [1,2])